The platform’s AI models are trained on clinical trials, molecular structures and regulatory documents
Life sciences consultancy firm AKT Health Inc has launched a life science and healthcare AI platform called Hakase AI, designed to streamline pharmaceutical development.
“Hakase AI is more than a platform; it’s an ecosystem designed to help pharmaceutical, biotech, and healthcare organizations navigate complexity with speed, precision, and impact,” said AKT Health president Aditya Kumar Tallapragada.
“We’re accelerating the path from discovery to delivery, ensuring life-changing therapies reach patients faster.”
Hakase AI integrates over 60 clinical, commercial and care datasets. Its AI models are trained on clinical trials, molecular structures and regulatory documents.
The training enables the use of predictive analytics, anticipating drug development outcomes and trends. It also optimises the design of clinical trials for faster, more efficient studies.
Drug discovery could be accelerated by Hakase AI, with the identification of promising compounds and the reduction of research and development timelines.
Outside of the research and development phase, the platform can also assist with market intelligence and care delivery.
Overall, the intention is that Hakase AI will cut out inefficiencies in the pharmaceutical development process and medical environments to accelerate the development and distribution of new treatments.
